Literature DB >> 26895488

The role of postoperative Tc-99m pertechnetate scintigraphy in estimation of remnant mass and prediction of successful ablation in patients with differentiated thyroid cancer.

Didem Ozdemir1, Fatma N Cuhaci, Elif Ozdemir, Cevdet Aydin, Reyhan Ersoy, Seyda Turkolmez, Bekir Cakir.   

Abstract

OBJECTIVE: Surgery and radioactive iodine (RAI) ablation constitute the mainstay of the treatment of differentiated thyroid carcinoma (DTC). In this study, we aimed to evaluate the diagnostic value of postoperative early Tc-99m pertechnetate scanning to detect remnant thyroid tissue and predict ablation success.
METHODS: DTC patients evaluated with postoperative Tc-99m pertechnetate scintigraphy and treated with RAI between January 2007 and December 2014 were recruited. The results of Tc-99m pertechnetate scanning were compared with therapeutic I-131 whole-body scanning (TxWBS) and diagnostic I-131 whole-body scanning (DxWBS) performed 6-9 months after RAI.
RESULTS: There were 154 (21.5%) male and 563 (78.5%) female patients, with a mean age of 49.11±12.35 years. Postoperative Tc-99m pertechnetate scanning was positive in 499 patients (69.6%) and negative in 218 (30.4%) patients. There were 673 (93.9%) patients with a positive TxWBS scan and 44 (6.1%) patients with negative TxWBS scan. Considering TxWBS as the standard test, sensitivity, specificity, positive predictive value, and negative predictive value of Tc-99m pertechnetate scanning were 72.2, 70.5, 97.4, and 14.2%, respectively. DxWBS was positive in 57 (9.0%) and negative in 564 (91%) patients. Ablation dose was higher and preablation thyroglobulin was lower in patients with negative DxWBS (P=0.001 and 0.04, respectively). Overall, 171 (92.9%) of 184 patients with negative Tc-99m pertechnetate had negative DxWBS.
CONCLUSION: Postoperative Tc-99m pertechnetate scintigraphy has a high positive predictive value to detect remnant tissue in patients with DTC. Although negative Tc-99m pertechnetate scanning does not indicate removal of all thyroid tissue, it is related to successful ablation in more than 90% of patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26895488     DOI: 10.1097/MNM.0000000000000492

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  4 in total

1.  99mTc-pertechnetate-avid metastases from differentiated thyroid cancer are prone to benefit from 131I therapy: A prospective observational study.

Authors:  Min Liu; Li Chai; Qiong Luo; Maomei Ruan; Lingxiao Cheng; Zhongwei Lv; Libo Chen
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

2.  99mTc-Pertechnetate Scintigraphy Predicts Successful Postoperative Ablation in Differentiated Thyroid Carcinoma Patients Treated with Low Radioiodine Activities.

Authors:  Luca Giovanella; Gaetano Paone; Teresa Ruberto; Luca Ceriani; Pierpaolo Trimboli
Journal:  Endocrinol Metab (Seoul)       Date:  2019-02-15

Review 3.  Hyperthyroid cats and their kidneys: a literature review.

Authors:  L Yu; L Lacorcia; T Johnstone
Journal:  Aust Vet J       Date:  2022-06-16       Impact factor: 1.343

4.  Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma.

Authors:  Liu Xiao; Wenjie Zhang; Hongmei Zhu; Yueqi Wang; Bin Liu; Rui Huang; Lin Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-27       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.